Highlight from Stem Cell Reports: New Type of Stem Cells Contains Potential for Knee Cartilage Regeneration in Arthritic Mice

Osteoarthritis (OA) is a debilitating joint disease which affects over 500 million people worldwide, with trends increasing as populations age. OA is caused by progressive, irreversible degeneration of joint cartilage, leading to pain, swelling and immobility in the affected joint. Current therapies focus on symptom relief but cannot restore degenerated cartilage.

A potentially alternative treatment is the regeneration of cartilage from stem cells. Importantly, not all types of stem cells can make cartilage and earlier clinical trials with mesenchymal stem or stromal cells (MSCs) obtained did not convincingly show that MSCs make new cartilage when given to OA patients. In search for the right type of stem cell for cartilage regeneration, Zhonghan Li and colleagues from Sichuan University, China, focused on so-called limb bud progenitor cells. During vertebrate embryogenesis, limb bud progenitor cells give rise to limb cartilage, bone, and tendon, suggesting that this type of stem cell has a naturally high intrinsic capacity to make cartilage. The work was recently published in the journal Stem Cell Reports.

To test this hypothesis, the researchers used genetic tools to isolate limb bud progenitors from developing mouse embryos. Remarkably, after injection into knee joints of mice with OA, the limb bud progenitor cells efficiently generated new cartilage whereas MSCs given to a separate group of mice failed to do so. Despite these encouraging results, limb bud progenitors are not readily obtainable from humans. To overcome this, Li and colleagues turned towards human pluripotent stem cells (hPSCs), which are immature stem cells that can be grown to high numbers in the lab. After extensive protocol optimization, the researchers indeed obtained hPSCs-derived limb bud progenitors which closely resembled embryonic limb bud progenitors according to gene and protein expression. Encouragingly, like their embryonic counterparts, hPSC-derived limb bud progenitors made new cartilage when transplanted into the knees of OA mice.

These findings set the stage for a potential cartilage replacement therapy for patients with OA, but further studies in animal models are required to confirm and replicate these findings. If such a treatment advances to the clinic it will need to pass proper regulatory review.

Paper: MSX1+PDGFRAlow limb mesenchyme-like cells as an efficient stem cell source for human cartilage regeneration

DOI: 10.1016/j.stemcr.2024.02.001

Scientist Contact: Zhonghan Li, Sichuan University, China, Zhonghan.li@scu.edu.cn

Image Title: MSX1+PDGFRAlow limb mesenchyme-like cells as an efficient stem cell source for human cartilage regeneration

Credit: Zhonghan Li

Contact Kym Kilbourne, Director of Media and Strategic Communications, ISSCR, for more information or to request the paper prior to publishing.

Previous
Previous

Bayer and BlueRock Therapeutics Join the City of Hamburg and Life Sciences Nord to Co-Sponsor ISSCR 2024 in Hamburg, Germany

Next
Next

Voting Opens for 2024 ISSCR Board of Directors and Officers